MedTrace Logo

Immediate Postoperative Adjuvant Hormonal Treatment in High Risk Localised or Locally Advanced Prostate Cancer Patients.

NCT01123434 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2015-01-08

No results posted yet for this study

Summary

The primary objective is to assess the efficacy of immediate postoperative adjuvant hormonal treatment according to 2 year PSA recurrence rate in high risk localised or locally advanced Chinese prostate cancer patients.The secondary objective is to assess the quality of life（QoL）of the high risk localised or locally advanced Chinese prostate cancer patients with immediate postoperative adjuvant hormonal treatment and get the information of immediate postoperative adjuvant hormonal treatment (including the regimen, dosage and duration).

Conditions

  • 2 Years PSA Recurrence Rate

Sponsors & Collaborators

Principal Investigators

  • Karen Atkin · AstraZeneca

  • Yanjing Zhang · AstraZeneca

  • Prof. Na · Peking University Shougang Hospital

  • Prof. Ye · Tong Ji Hospital of Tongji Medical College of Huazhong University of Science and Technology

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2014-08-31
Completion
2014-08-31

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01123434 on ClinicalTrials.gov